NewsRx.com
June 26, 2008
Bionovo Inc. announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and osteoporosis. The data, which were presented at the Endocrine Society's 90th Annual Meeting, showed that the new regulatory elements are essential for the differentiation of the estrogenic pharmacological activity exerted by different compounds.
"Selective estrogen receptor modulators (SERMs) differ from estrogen in how they regulate gene transcription and result in different pharmacological profiles and clinical effects," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. "This study identified gene elements that are activated by SERMs but not by estrogens used in hormone therapy. The identification of these elements, coupled with the understanding of the differential regulation in various tissues, provides a new platform for the discovery of estrogenic drugs with SERM-like profiles."
The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.
"The discovery of these selective estrogen regulatory elements strengthens our SERM discovery engine," said Isaac Cohen, Bionovo's chairman and chief executive officer. "The advantage of the new array of specific regulatory elements is manifest in the pharmacological and toxicological insights gained. We can now acquire higher predictive value and greater specificity from a very complex biological system. I believe this puts Bionovo at the forefront of more rapidly developing future SERM products which are far more specific."
Copyright 2008, OBGYN & Reproduction Week via NewsRx.com
